Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience | Zendy

Luís Felipe Ensina | Zendy; Solange Oliveira Rodrigues Valle | Zendy; Ana Paula Juliani | Zendy; Michel Galeane | Zendy; R. Vieira dos Santos | Zendy; L. Karla Arruda | Zendy; Janaína Michelle Lima Melo | Zendy; Patrícia Karla de Souza | Zendy; Faradiba Sarquis Serpa | Zendy; Djanira Andrade | Zendy; Alfeu Tavares França | Zendy; Régis A. Campos | Zendy; Inês Cristina CameloNunes | Zendy; Dirceu Solé | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience

Author(s) -

Luís Felipe Ensina,

Solange Oliveira Rodrigues Valle,

Ana Paula Juliani,

Michel Galeane,

R. Vieira dos Santos,

L. Karla Arruda,

Janaína Michelle Lima Melo,

Patrícia Karla de Souza,

Faradiba Sarquis Serpa,

Djanira Andrade,

Alfeu Tavares França,

Régis A. Campos,

Inês Cristina CameloNunes,

Dirceu Solé

Publication year - 2016

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000444985

Subject(s) - omalizumab , medicine , refractory (planetary science) , chronic urticaria , adverse effect , antihistamine , gastroenterology , immunoglobulin e , immunology , antibody , physics , astrobiology

Current guidelines on chronic spontaneous urticaria (CSU) suggest a treatment based on a 3-step approach that aims at total symptom control, starting with H1-antihistamines. However, a significant number of patients present an antihistamine-resistant urticaria that must be treated with an alternative third-line therapy such as omalizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research